In Parkinson's disease (PD), among the clinical and symptomatic manifestations of the disease in recent years, attention has been increasingly paid to the so-called non-motor symptoms, that is, cognitive disorders. In PD, cognitive disorders can manifest themselves in the form of a decrease in executive, visual, and visuospatial activity and memory impairment from mild to severe dementia. Cognitive impairments of a subjective and objective nature are often found at the level of early and mild manifestations. In such situations, it is important to develop a strategy for predicting the progression of cognitive disorders and developing methods for their prevention. Long-term and multicenter studies conducted over the past 30-40 years have shown that after the diagnosis of PD, dementia develops after ten courses of the underlying disease. This, in turn, aggravates the already complex course of PD with a pronounced decrease in the quality of life of patients.

Parkinson's disease, cognitive disorders, dementia

Clinical diagnostic criteria for dementia associated with Parkinson's disease. / M. Emre, D. Aarsland, R. Brown, et al. // Mov. Disord. – 2017;22(12):1689-1707

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. / I. Litvan, J.G. Goldman, A.I. Tröster, et al. // Mov. Disord. - 2016;27(3):349-356.

Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. / P. Svenningsson, E. Westman, C. Ballard, D. Aarsland. // Lancet Neurol. - 2015;11(8):697-707.

Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. / K.F. Pedersen, J.P. Larsen, O.B. Tysnes, G. Alves. // JAMA Neurol. – 2015;70:580–586.

The distinct cognitive syndromes of Parkinson's disease: 5-year follow-up of the CamPaIGN cohort. / C.H. Williams-Gray, J.R. Evans, A. Goris, et al. // Brain. - 2011;132(11):2958-2969.

The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. / C.H. Williams-Gray, S.L. Mason, J.R. Evans, et al. // J. Neurol. Neurosurg. Psychiatry. - 2016;84(11):1258-1264.

Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. / G. Santangelo, C. Vitale, M. Picillo, et al. // Parkinsonism Relat Disord. - 2015;21(10):1219-1226.

Longitudinal study of normal cognition in Parkinson's disease. / K. Pigott, J. Rick, S.X. Xie, et al. // Neurology. - 2015;85(15):1276-1282.

Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. / C.H. Williams-Gray, A. Hampshire, T.W. Robbins, et al. // J. Neurosci. - 2017;27(18):4832-4838.

Kehagia A.A., Barker R.A., Robbins T.W. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. // Neurodegener Dis. - 2013;11(2):79-92.

Different PD-MCI criteria and risk of dementia in Parkinson's disease: a 4-year longitudinal study. / K.L. Wood, D.J. Myall, L. Livingston, et al. // NPJ Parkinsons Dis. - 2016;2:15027.

Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. / D.H. Ffytche, J.B. Pereira, C. Ballard, et al. // J Neurol Neurosurg Psychiatry. - 2017;88(4):325-331.

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. / D. Aarsland, K. Andersen, J.P. Larsen, et al. // Arch. Neurol. - 2015;60(3):387-392.

Predictors of dementia in Parkinson disease: a prospective cohort study. / J.B. Anang, J.F. Gagnon, J.A. Bertrand, et al. // Neurology. - 2016;83(14):1253-1260.

Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. / D.C. Backstrom, M. Eriksson Domellof, J. Linder, et al. // JAMA Neurol. - 2015;72(10):1175-1182.

CSF biomarkers and clinical progression of Parkinson's disease. / S. Hall, Y. Surova, A. Qhrfelt, et al. // Neurology. - 2015;84(1):57-63.

CSF Aβ42 predicts early-onset dementia in Parkinson's disease. / G. Alves, J. Lange, K. Blennow, et al. // Neurology. - 2014;82(20):1784-1790.

CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson's Disease. / M.Jr. Terrelonge, K.S. Marder, D. Weintraub, R.N. Alcalay. // J. Mol. Neurosci. - 2016;58(1):88-92.

COPPADIS-2015, a global--clinical evaluation, serum biomarkers, genetic studies and neuroimaging, is a prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. / D. Santos-García, P. Mir, E. Cubo, COPPADIS Study Group., et al. // BMC Neurol. - 2016;16:26.

Politis M., Su P., Piccini P. Imaging of microglia in patients with neurodegenerative disorders. // Front Pharmacol. - 2012;3:96.

The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. / K. Wu, D. O'Keeffe, M. Politis, et al. // Brain. - 2012;135(8):2449-2457.

Impaired cognitive performance and hippocampal atrophy in Parkinson's disease. / D. Yildiz, S. Erer, M. Zarifoğlu, et al. // Turk. J. Med. Sci. - 2015;45(5):1173-1177.

Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. / E. Mak, L. Su, G.B. Williams, et al. // Brain. - 2015;138(10):2974-2986.

Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease. / J.B. Pereira, D. Aarsland, C.E. Ginestet, et al. // Hum. Brain Mapp. - 2015;36(8):2980-2995.

Mild cognitive impairment is linked with a faster rate of cortical thinning in patients with Parkinson's disease longitudinally. / A. Hanganu, C. Bedetti, C. Degroot, et al. // Brain. - 2014;137(4):1120-1129.

Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia. / B.Borroni, E. Premi, A. Formenti, et al. // Parkinsonism Relat Disord. - 2015;21(9):1049-1055.

Quantitative EEG analysis of executive dysfunction in Parkinson's disease. / S. Kamei, A. Morita, K. Serizawa, et al. // J. Clin. Neurophysiol. - 2016;27(3):193-197.

Morita A., Kamei S., Mizutani T. Relationship between slowing of the EEG and cognitive impairment in Parkinson's disease. // J. Clin. Neurophysiol. - 2016;28(4):384–387.

Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease. / J.H. Caviness, J.G. Hentz, C.M. Belden, et al. // J. Parkinsons Dis. - 2015;5(1):117-24.

30. Correlation of EEG slowing with cognitive domains in nondemented patients with Parkinson's disease. / R. Zimmermann, U. Gschwandtner, F. Hatz, et al. // Dement Geriatr Cogn Disord. 2015;39(3-4):207-14.

Comparison of quantitative EEG between patients with Alzheimer's disease and those with Parkinson's disease dementia. / L.C. Fonseca, G.M. Tedrus, P.N. Carvas, E.C. Machado. // Clin. Neurophysiol. - 2016;124(10):1970-1974.

Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. / Y. Compta, N. Ibarretxe-Bilbao, J.B. Pereira, et al. // Parkinsonism Relat Disord. - 2015;18(8):941-947.

Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. / Y. Compta, J.B. Pereira, J. Ríos, et al. // Parkinsonism Relat Disord. - 2013;19(8):717-724.